Pfizer announces availability of CIBINQO ®▼ (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis in Ireland

CIBINQO ^® is a once-daily oral treatment with proven efficacy demonstrated in a large-scale clinical trial program

Pfizer Healthcare Ireland has today announced the availability of the 50 mg, 100 mg and 200 mg doses of CIBINQO ^® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy, in Ireland.